In most of the aforementioned cancers, increased CDK5 and/or activator expression matches with poor prognosis, lymph node metastasis, and overall poor survival, while low CDK5 levels correlate with metastasis-free disease [37]. This evidence concerns the gene CDK5 and metastatic malignant neoplasm in the lymph nodes.